These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21810389)

  • 1. Effectiveness of bosentan in the treatment of ischemic lesions in a case of thromboangiitis obliterans (Buerger disease): a case report.
    Palomo-Arellano A; Cervigón-González I; Torres-Iglesias LM
    Dermatol Online J; 2011 Jul; 17(7):4. PubMed ID: 21810389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of bosentan in digital ischemic ulcers.
    Todoli Parra JA; Hernández MM; Arrébola López MA
    Ann Vasc Surg; 2010 Jul; 24(5):690.e1-4. PubMed ID: 20579585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of thromboangiitis obliterans (Buerger's disease) with high-potency vasodilators.
    Jiménez-Gallo D; Albarrán-Planelles C; Arjona-Aguilera C; Blanco-Sánchez G; Rodríguez-Mateos ME; Linares-Barrios M
    Dermatol Ther; 2015; 28(3):135-9. PubMed ID: 25649782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of bosentan in patients with refractory thromboangiitis obliterans (Buerger disease): A case series and review of the literature.
    Narváez J; García-Gómez C; Álvarez L; Santo P; Aparicio M; Pascual M; López de Recalde M; Borrell H; Nolla JM
    Medicine (Baltimore); 2016 Nov; 95(48):e5511. PubMed ID: 27902617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of bosentan in the treatment of digital ulcers secondary to thromboangiitis obliterans].
    Prior Á; Rodriguez-Muguruza S; Sanint J; Olivé A
    Med Clin (Barc); 2015 Jul; 145(1):44. PubMed ID: 25433787
    [No Abstract]   [Full Text] [Related]  

  • 6. An open-label study on long-term outcomes of bosentan for treating ulcers in thromboangiitis obliterans (Buerger's disease).
    De Haro J; Bleda S; Acin F
    Int J Cardiol; 2014 Dec; 177(2):529-31. PubMed ID: 25217217
    [No Abstract]   [Full Text] [Related]  

  • 7. [Thromboangiitis obliterans (Buerger disease) discovered by symptoms of arthralgia in a young woman].
    Kovacsovics-Bankowski M; Gerster JC
    Praxis (Bern 1994); 1997 Dec; 86(49):1945-8. PubMed ID: 9480517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thromboangiitis obliterans (Buerger's disease).
    Klein-Weigel PF; Richter JG
    Vasa; 2014 Sep; 43(5):337-46. PubMed ID: 25147010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buerger disease (thromboangiitis obliterans): a clinical diagnosis.
    Highlander P; Southerland CC; VonHerbulis E; Gonzalez A
    Adv Skin Wound Care; 2011 Jan; 24(1):15-7. PubMed ID: 21173586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A role of endothelin 1 in the pathogenesis of thromboangiitis obliterans (initital news)].
    Czarnacki M; Gacka M; Adamiec R
    Przegl Lek; 2004; 61(12):1346-50. PubMed ID: 15850327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Buerger disease (thromboangiitis obliterans) with bosentan: a case report.
    De Haro J; Florez A; Fernandez JL; Acin F
    BMJ Case Rep; 2009; 2009():. PubMed ID: 21686681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inpatient treatment of severe nicotine dependence in a patient with thromboangiitis obliterans (Buerger's disease).
    Hooten WM; Bruns HK; Hays JT
    Mayo Clin Proc; 1998 Jun; 73(6):529-32. PubMed ID: 9621859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spinal cord stimulation for the treatment of Buerger disease: a report on 3 cases.
    Fabregat G; Villanueva VL; Asensio JM; De Andrés J; López D
    Clin J Pain; 2011; 27(9):819-23. PubMed ID: 21593666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of multiple refractory ankle ulcerations in thromboangiitis obliterans: A case report.
    Huang ZH; Kuo SY; Chiu YH; Chen HC; Lu CC
    Medicine (Baltimore); 2018 May; 97(20):e10798. PubMed ID: 29768374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of thromboangiitis obliterans (Buerger's disease) with bosentan.
    De Haro J; Acin F; Bleda S; Varela C; Esparza L
    BMC Cardiovasc Disord; 2012 Feb; 12():5. PubMed ID: 22333218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bosentan and sildenafil: successful treatment in a sclerodermic patient with refractory ulcers.
    Catarsi E; Doveri M; Tavoni A
    Reumatismo; 2013 May; 65(2):79-81. PubMed ID: 23877412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intestinal ischemia as a single manifestation of thromboangiitis obliterans--a case report.
    Magalhães Ede P; Trevisan M; Mochizuki M; Sachetto Z; Samara AM; Fernandes SR
    Angiology; 2005; 56(6):789-92. PubMed ID: 16327959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of eNOS and ET-1 polymorphisms in thromboangiitis obliterans.
    Adigüzel Y; Yilmaz E; Akar N
    Clin Appl Thromb Hemost; 2010 Feb; 16(1):103-6. PubMed ID: 19520685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buerger disease (thromboangiitis obliterans).
    Del Conde I; Peña C
    Tech Vasc Interv Radiol; 2014 Dec; 17(4):234-40. PubMed ID: 25770636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.
    Korn JH; Mayes M; Matucci Cerinic M; Rainisio M; Pope J; Hachulla E; Rich E; Carpentier P; Molitor J; Seibold JR; Hsu V; Guillevin L; Chatterjee S; Peter HH; Coppock J; Herrick A; Merkel PA; Simms R; Denton CP; Furst D; Nguyen N; Gaitonde M; Black C
    Arthritis Rheum; 2004 Dec; 50(12):3985-93. PubMed ID: 15593188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.